myeloma

(redirected from myelomas)
Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to myelomas: multiple myeloma

myeloma

 [mi″ĕ-lo´mah]
1. a tumor composed of plasma cells of the type normally found in the bone marrow.
giant cell myeloma giant cell tumor (def. 1).
multiple myeloma see multiple myeloma.
plasma cell myeloma multiple myeloma.
solitary myeloma a variant of multiple myeloma in which there is a single localized tumor focus. Called also plasma cell tumor.

my·e·lo·ma

(mī'ĕ-lō'mă),
1. A tumor composed of cells derived from hemopoietic tissues of the bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

myeloma

(mī′ə-lō′mə)
n. pl. myelo·mas or myelo·mata (-mə-tə)
A malignant tumor formed by the cells of the bone marrow.

my′e·lo′ma·toid′ (-toid′) adj.

myeloma

Malignant plasmacytoma, multiple myeloma, multiple plasmacytoma of bone, myelomatosis, plasma cell myeloma Hematology A neoplastic proliferation of plasma cells in BM and extramedullary sites; if circumscribed, plasmacytoma Epidemiology MM comprises 10% of hematopoietic malignancies, causing 10,000 deaths/yr–US; ↑ with age; black:white 2:1 Clinical As the myeloma cells proliferate in BM, they cause osteolysis, resulting in pathologic fractures and industrial strength pain, anorexia, nausea, thirst, fatigue, muscle weakness, restlessness, confusion; BM replacement by neoplastic plasma cells results in ↑ infections and anemia due to displacement of normal WBCs, and erythroid series; excess Igs in circulation plug up renal tubules Lab Monoclonal Igs, often light chains, in serum, urine; ↑ Ca2+; normal PO4, normal alk phos Complications Painful pathologic fractures, anemia, hypercalcemia, renal failure, recurrent bacterial infections Treatment 1º chemotherapy: Melphalan and prednisone; VAD–vincristine, Adriamycin, dexamethasone in new cases; IFN-α has been used for maintenance; myeloablative therapy, allogeneic BMT from HLA-matched siblings. See Clear cell, myeloma, Indolent myeloma, Myeloma kidney, Solitary myeloma.

my·e·lo·ma

(mī'ĕ-lō'mă)
1. A tumor composed of cells derived from hemopoietic tissues of the bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

myeloma

A tumour derived from a lymphocyte. See LYMPHOMA, MYELOMATOSIS.

myeloma

a cancerous tumour of the bone marrow.

Myeloma

A tumor that originates in bone marrow and usually spreads to more than one bone.

my·e·lo·ma

(mī'ĕ-lō'mă)
1. A tumor composed of cells derived from hemopoietic tissues of bone marrow.
2. A plasma cell tumor.
[myelo- + G. -oma, tumor]

Patient discussion about myeloma

Q. Multiple Myeloma what and how is it treated and what is MGUF

A. Were you referring by any chance to MGUS (monoclonal gammopathy of unknown significance)? It's a condition that resembles myeloma but is much more widespread and by itself isn't considered malignant. It may, however, deteriorate to multiple myeloma over the years.

Myeloma is treated with chemotherapy of various kinds, and sometimes with bone marrow transplantation with the patients own bone marrow.

You may read more here:
www.nlm.nih.gov/medlineplus/multiplemyeloma.html

More discussions about myeloma
References in periodicals archive ?
Dagrada et al., "The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance," Haematologica, vol.
Kuehl, "Characterization of MYC translocations in multiple myeloma cell lines," Journal of the National Cancer Institute, no.
The natural history of extramedullary plasmacytoma and its relation to solitary myeloma of bone and myelomatosis.
These findings were consistent with multiple myeloma. Furthermore, the trephine biopsy sections showed interstitial infiltration of the bone marrow by sheets and clusters of plasma cells (Figure 3).
Immunoglobulin D multiple myeloma (IgD MM) was first recognized by Rowe and Fahey in 1965 (6).
Statistics prove that informed myeloma patients live longer.
Gary Petersen goes a step further when he says, "The Myeloma Cure Panels save life!
* SPEP may reveal a small or absent monoclonal spike in IgD myeloma.
* SPEP without a distinct monoclonal band in the [beta] or [gamma] region and monoclonal light chains on serum or urine immunofixation without a corresponding IgA, IgG, or IgM component are consistent with both light chain disease and IgD myeloma, and should prompt immunofixation for IgD.
Multiple myeloma was diagnosed in a wide age range of 26 to 82 years with a median age of 58 years.
There is some data suggesting that the risk of progression to multiple myeloma from a solitary primary lymph node plasmacytoma is less than for other extramedullary plasmacytomata and that recurrence posttreatment is rare [6], but evidence is limited to small case series and individual case reports.
Even within a patient, different myeloma cells gain different genetic profiles as the disease evolves, which means some treatments may work against only part of the cancer.